Cite
HARVARD Citation
Yang, J. et al. (2023). Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion–positive non–small cell lung cancer. Expert review of anticancer therapy. 23 (1), pp. 95-106. [Online].